Amicus Therapeutics Inc.

Cranbury, N.J. • 609-662-2000 •

Exchange and Ticker: Nasdaq: FOLD

Filing Range: 5.00M shares @ $14.00 to $16.00

Offering Price: $15.00

Close on First Day: $14.43

Offering Size: $75.00M

Shares Outstanding: 22,234,426M

Underwriters: Morgan Stanley/ Merrill Lynch

Co-managers: JP Morgan/ Lazard Capital Markets/ Pacific Growth Equities Inc.

Company Counsel: Bingham McCutchen LLP

Manager Counsel: Ropes & Gray

Auditor: Ernst & Young LLP

Market Capitalization on 5/31/07: $320.84M

Close price at current month end: $14.43


Develops a family of small-molecule therapeutics that treats genetic disorders based on the company’s proprietary technology. The company’s technology therapies apply to conditions in which crucial proteins are defective as a result of improper folding. Instead of trying to replace these complex proteins, Amicus’ approach uses pharmacological chaperones to selectively bind the misfolded target protein and help the protein fold into its proper three-dimensional shape. Competitors include Genzyme Corp., Transkaryotic Therapies, BioMarin, and Large Scale Biology Corp.


Canaan Partners, CHLMedical Partners, Frazier Healthcare and Technology Ventures, New Enterprise Associates, Palo Alto Investors, Prospect Venture Partners, Quaker BioVentures Inc., Radius Ventures LLC, Och-Ziff Capital Management Group.

Source: Thomson Financial